Wynveris receives CHF 40,000 from Venture Kick to advance first-in-class breast cancer therapy

What's the deal? Swiss biotech startup WynverisDealroom has a profile for this one. Try Dealroom → has secured CHF 40,000 in Stage 2 funding from Venture KickDealroom has a profile for this one. Try Dealroom → to develop what it calls the first receptor-selective FZD5 inhibitor for triple-negative breast cancer — one of the most aggressive and hard-to-treat forms of the disease.

The therapy is designed to overcome drug resistance and boost the effectiveness of existing cancer treatments. Beyond the lead programme, Wynveris aims to build a broader receptor-selective WNT platform targeting cancers driven by WNT signalling.

Why now? Wynveris had already generated strong in vivo efficacy data and a clean safety profile before entering Venture Kick, but the science had outgrown what academic funding could support. The company's compounds reached sub-nanomolar potency, revealing a large intellectual property space with clinical-candidate potential.

"It became clear that we hadn't just discovered a promising compound, but an entire high-quality chemical space," the team said. That realisation shifted the focus from proving a scientific concept to building a company.

What could go wrong? CHF 40,000 is a modest sum in drug development, where taking a single candidate through preclinical work can cost millions. The funding will support in vitro and in vivo validation studies and help Wynveris select a development candidate — but the startup will need significantly larger financing rounds to reach the clinic.

Triple-negative breast cancer is a notoriously difficult target, and WNT-pathway therapies have historically struggled with toxicity and selectivity. Wynveris will need to demonstrate that its receptor-selective approach avoids these pitfalls.

The signal: Wynveris is part of a growing wave of early-stage oncology startups pursuing receptor-selective strategies over broad-spectrum WNT inhibition — an approach that has historically failed in the clinic due to toxicity concerns. With sub-nanomolar potency and a clean safety profile already demonstrated in vivo, the company's platform thesis could position it as an attractive acquisition or partnering target for larger pharma players seeking precision oncology assets in the WNT pathway space.

Read more: venturekick.ch